SynthesisCancer medicine2023

Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.

Shang-Hsuan Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.